|
1
|
Strober W, Fuss I and Mannon P: The
fundamental basis of inflammatory bowel disease. J Clin Invest.
117:514–521. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
2
|
Talley NJ, Abreu MT, Achkar JP, Bernstein
CN, Dubinsky MC, Hanauer SB, Kane SV, Sandborn WJ, Ullman TA and
Moayyedi P; American College of Gastroenterology IBD Task Force, :
An evidence-based systematic review on medical therapies for
inflammatory bowel disease. Am J Gastroenterol. 106 (Suppl
1):S2–S25; quiz S26. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lee JY, Wasinger VC, Yau YY, Chuang E,
Yajnik V and Leong RW: Molecular pathophysiology of epithelial
barrier dysfunction in inflammatory bowel diseases. Proteomes.
6:E172018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Camilleri M, Madsen K, Spiller R,
Greenwood-Van Meerveld B and Verne GN: Intestinal barrier function
in health and gastrointestinal disease. Neurogastroenterol Motil.
24:503–512. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ma TY, Iwamoto GK, Hoa NT, Akotia V,
Pedram A, Boivin MA and Said HM: TNF-alpha-induced increase in
intestinal epithelial tight junction permeability requires NF-kappa
B activation. Am J Physiol Gastrointest Liver Physiol.
286:G367–G376. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ivanov AI, Nusrat A and Parkos CA: The
epithelium in inflammatory bowel disease: Potential role of
endocytosis of junctional proteins in barrier disruption. Novartis
Found Symp. 263:115–124; discussion 124–132, 211–218.
2004.PubMed/NCBI
|
|
7
|
Niessen CM: Tight junctions/adherens
junctions: Basic structure and function. J Invest Dermatol.
127:2525–2532. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Turner JR: Intestinal mucosal barrier
function in health and disease. Nat Rev Immunol. 9:799–809. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Laukoetter MG, Nava P, Lee WY, Severson
EA, Capaldo CT, Babbin BA, Williams IR, Koval M, Peatman E,
Campbell JA, et al: JAM-A regulates permeability and inflammation
in the intestine in vivo. J Exp Med. 204:3067–3076. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Arrieta MC, Madsen K, Doyle J and Meddings
J: Reducing small intestinal permeability attenuates colitis in the
IL10 gene-deficient mouse. Gut. 58:41–48. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Edelblum KL and Turner JR: The tight
junction in inflammatory disease: Communication breakdown. Curr
Opin Pharmacol. 9:715–720. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Arnott ID, Kingstone K and Ghosh S:
Abnormal intestinal permeability predicts relapse in inactive Crohn
disease. Scand J Gastroenterol. 35:1163–1169. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ahmad TB, Liu L, Kotiw M and Benkendorff
K: Review of anti-inflammatory, immune-modulatory and wound healing
properties of molluscs. J Ethnopharmacol. 210:156–178. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Gao L, Jia C, Zhang H and Ma C: Wenjing
decoction (herbal medicine) for the treatment of primary
dysmenorrhea: A systematic review and meta-analysis. Arch Gynecol
Obstet. 296:679–689. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhang LJ, Zhu JY, Sun MY, Song YN, Rahman
K, Peng C, Zhang M, Ye YM and Zhang H: Anti-inflammatory effect of
Man-Pen-Fang, a Chinese herbal compound, on chronic pelvic
inflammation in rats. J Ethnopharmacol. 208:57–65. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wang XY and Tian DL: Etiological and
pathological characteristics of ulcerative colitis and TCM
differentiation and treatment. Beijing Zhong Yi Yao Da Xue Xue Bao.
30:554–559. 2007.(In Chinese).
|
|
17
|
Gong YP, Liu W, Ma GT, Hu HY, Xie JQ, Tang
ZP, Hao WW, Bian H, Zhu LY, et al: Randomized control study of
‘Qingchang Suppository’ on ulcerative colitis. Shanghai Zhong Yi
Yao Da Xue Xue Bao. 21:33–36. 2007.(In Chinese).
|
|
18
|
Fu NL and Huang JY: Progress of clinical
research of traditional Chinese medicine for the treatment of
ulcerative colitis. J Tradit Chin Med. 40:501–503. 1999.(In
Chinese).
|
|
19
|
Li QG: An idea about treatment of
ulcerative colitis by TCM methods. Beijing Zhong Yi. 23:149–150.
2004.(In Chinese).
|
|
20
|
Wang CH, Gao WY, Li YF, Chen SQ, Yang Z,
Lu YP, Gong Y and Liu Y: Study of Fufangkushen colon-release
capsule on ulcerative colitis of endo-retention of damp heat type.
Xian Dai Zhong Xi Yi Jie He Za Zh. 18:13–15. 2009.(In Chinese).
|
|
21
|
Chen JT, Ke X, Fu XY, Wang WR, Hu GH and
Yang CB: The clinical study of heat-clearing and damp-drying on the
treatment of damp-heat ulcerative colitis. Zhongguo Zhong Xi Yi Jie
He Xiao Hua Za Zh. 17:256–258. 2009.(In Chinese).
|
|
22
|
Ke X, Hu G, Fang W, Chen J, Zhang X, Yang
C, Peng J, Chen Y and Sferra TJ: Qing Hua Chang Yin inhibits the
LPS-induced activation of the IL-6/STAT3 signaling pathway in human
intestinal Caco-2 cells. Int J Mol Med. 35:1133–1137. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ke X, Chen J, Zhang X, Fang W, Yang C,
Peng J, Chen Y and Sferra TJ: Qing Hua Chang Yin attenuates
lipopolysaccharide-induced inflammatory response in human
intestinal cells by inhibiting NF-κB activation. Exp Ther Med.
6:189–193. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ke X, Zhou F, Gao Y, Xie B, Hu G, Fang W,
Peng J, Chen Y and Sferra TJ: Qing Hua Chang Yin exerts therapeutic
effects against ulcerative colitis through the inhibition of the
TLR4/NF-κB pathway. Int J Mol Med. 32:926–930. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Amasheh M, Grotjohann I, Amasheh S, Fromm
A, Söderholm JD, Zeitz M, Fromm M and Schulzke JD: Regulation of
mucosal structure and barrier function in rat colon exposed to
tumor necrosis factor alpha and interferon gamma in vitro: A novel
model for studying the pathomechanisms of inflammatory bowel
disease cytokines. Scand J Gastroenterol. 44:1226–1235. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Δ Δ C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Berends SE, Strik AS, Löwenberg M, D'Haens
GR and Mathôt RAA: Clinical Pharmacokinetic and Pharmacodynamic
Considerations in the Treatment of Ulcerative Colitis. Clin
Pharmacokinet. 58:15–37. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kondamudi PK, Malayandi R, Eaga C and
Aggarwal D: Drugs as causative agents and therapeutic agents in
inflammatory bowel disease. Acta Pharm Sin B. 3:289–296. 2013.
View Article : Google Scholar
|
|
29
|
Suzuki T: Regulation of intestinal
epithelial permeability by tight junctions. Cell Mol Life Sci.
70:631–659. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ke X, Liu L, Zhao P, Chen Y, Peng J, Fang
W, Chen J, Hu G, Gao Y, Shen A, et al: The effects of Qing Hua
Chang Yin on the epithelial tight junctions of mice with
inflammatory bowel disease. Int J Clin Exp Med. 12:6864–6873.
2019.
|
|
31
|
Liu J, Lu XJ, Tian XM, Shen XP and Bao XP:
Antipyretic effects of Xinhuang Tablets on various animal fever
models. Drugs Clin. 4:375–379. 2015.(In Chinese).
|
|
32
|
Chen C, Bao XP, Qiu CX, Wang CF, Nan SH,
Huang WQ and Wang RG: Effects of Xinhuang tablets and its chinese
medicine components on high uric acid mice caused by hypoxanthine.
Strait Pharm J. 1:21–23. 2015.(In Chinese).
|
|
33
|
Putt KK, Pei R, White HM and Bolling BW:
Yogurt inhibits intestinal barrier dysfunction in Caco-2 cells by
increasing tight junctions. Food Funct. 8:406–414. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Gasparetto M and Guariso G: Highlights in
IBD epidemiology and its natural history in the paediatric age.
Gastroenterol Res Pract. 2013:8290402013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Piche T, Barbara G, Aubert P, Bruley des
Varannes S, Dainese R, Nano JL, Cremon C, Stanghellini V, De
Giorgio R, Galmiche JP, et al: Impaired intestinal barrier
integrity in the colon of patients with irritable bowel syndrome:
Involvement of soluble mediators. Gut. 58:196–201. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zhou Q, Zhang B and Verne GN: Intestinal
membrane permeability and hypersensitivity in the irritable bowel
syndrome. Pain. 146:41–46. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Camilleri M and Gorman H: Intestinal
permeability and irritable bowel syndrome. Neurogastroenterol
Motil. 19:545–552. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Van Itallie CM, Fanning AS, Bridges A and
Anderson JM: ZO-1 stabilizes the tight junction solute barrier
through coupling to the perijunctional cytoskeleton. Mol Biol Cell.
20:3930–3940. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Fanning AS and Anderson JM: Zonula
occludens-1 and −2 are cytosolic scaffolds that regulate the
assembly of cellular junctions. Ann N Y Acad Sci. 1165:113–120.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Hamada K, Shitara Y, Sekine S and Horie T:
Zonula Occludens-1 alterations and enhanced intestinal permeability
in methotrexate-treated rats. Cancer Chemother Pharmacol.
66:1031–1038. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Al-Sadi R, Khatib K, Guo S, Ye D, Youssef
M and Ma T: Occludin regulates macromolecule flux across the
intestinal epithelial tight junction barrier. Am J Physiol
Gastrointest Liver Physiol. 300:G1054–G1064. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Zeissig S, Bürgel N, Günzel D, Richter J,
Mankertz J, Wahnschaffe U, Kroesen AJ, Zeitz M, Fromm M and
Schulzke JD: Changes in expression and distribution of claudin 2, 5
and 8 lead to discontinuous tight junctions and barrier dysfunction
in active Crohn's disease. Gut. 56:61–72. 2007. View Article : Google Scholar : PubMed/NCBI
|
